NLINKN1 Chip+PRIME.StudySYNCRStentrode+$75M.SeriesDPRECNLayer 7+FDA.BrkthruPARAMArgo+$20M.SeriesBBLKRKNeuroport+200.ImplantsEMTIVMN8+$45M.SeriesBKRNLFlux+Non-invasiveNRBLEHalo+Consumer.BCINEURONeuroPace+RNS.SystemCOGNICognixion+ALS.TrialFUND.YTD2026$2.8B.SectorTRIALSActive50+.ClinTrialsIMPLNTSHumans~100.Intracrtnl
Terminal/Device DB/Layer 7 Cortical Interface
ECoGIDEinvestigational

Layer 7 Cortical Interface

Implant Type
ECoG
Electrodes
1,024
Channels
1,024
FDA Status
IDE
Clinical Stage
PATTERN I feasibility (acute intraoperative)
Status
investigational
About

Precision Neuroscience's Layer 7 is a high-density electrocorticography (ECoG) array — a thin, flexible film containing 1,024 electrodes that rests on the surface of the cortex without penetrating brain tissue. Unlike intracortical approaches, Layer 7 is placed subdurally via a minimally invasive slit craniotomy. Because the electrodes sit on the cortical surface rather than piercing it, the device is theoretically reversible and associated with a lower inflammatory response than penetrating arrays. The PATTERN I trial conducts acute intraoperative recordings during elective neurosurgical procedures to validate signal quality and safety. Precision was co-founded by former Neuralink engineers Benjamin Rapoport and Vindum Vedam-Mai.

Target Conditions
motor paralysisALSspeech restorationintraoperative cortical mapping
Milestones
2021-06Precision Neuroscience founded by former Neuralink engineers
2022-10First human intraoperative recording with Layer 7
2023-03FDA IDE granted for PATTERN I study
2024-0150+ intraoperative sessions completed
2024-06$93M Series C announced
FDA Regulatory Pathway
Investigational Device Exemption (IDE)

An IDE permits a device to be used in a clinical study to collect safety and effectiveness data required for a PMA or 510(k) submission. IDE devices are not approved for commercial sale.

FDA Device Regulatory Guidance ↗
Other ECoG Devices